| Journal Article |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| A Comparison of the Cost Effectiveness of Pharmacotherapy or Surgery (Laparoscopic Fundoplication) in the Treatment of GORD |
0 |
0 |
0 |
29 |
1 |
3 |
6 |
289 |
| A Framework for Using Cost-effectiveness Analysis to Support Pricing and Reimbursement Decisions for New Pharmaceuticals in a Context of Evolving Treatments, Prices, and Evidence |
0 |
0 |
1 |
1 |
3 |
6 |
11 |
12 |
| Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments required |
0 |
0 |
0 |
0 |
2 |
5 |
16 |
18 |
| Acknowledging Patient Heterogeneity in Economic Evaluation |
0 |
0 |
0 |
6 |
1 |
3 |
7 |
33 |
| Adherence to the iDSI reference case among published cost-per-DALY averted studies |
0 |
0 |
0 |
0 |
8 |
9 |
14 |
16 |
| After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator? |
0 |
0 |
0 |
5 |
0 |
1 |
3 |
34 |
| An Iterative Bayesian Approach to Health Technology Assessment: Application to a Policy of Preoperative Optimization for Patients Undergoing Major Elective Surgery |
0 |
0 |
0 |
1 |
0 |
0 |
3 |
6 |
| An economic model for the prevention of MRSA infections after surgery: non-glycopeptide or glycopeptide antibiotic prophylaxis? |
0 |
0 |
0 |
6 |
3 |
4 |
7 |
55 |
| Assessing Generalisability in Model-Based Economic Evaluation Studies |
0 |
0 |
0 |
22 |
1 |
1 |
3 |
146 |
| Assessing generalisability by location in trial‐based cost‐effectiveness analysis: the use of multilevel models |
0 |
0 |
0 |
54 |
2 |
3 |
13 |
174 |
| Assessing the Cost-Effectiveness of New Pharmaceuticals in Epilepsy in Adults: The Results of a Probabilistic Decision Model |
0 |
0 |
0 |
1 |
1 |
3 |
6 |
13 |
| Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England |
0 |
0 |
0 |
0 |
0 |
1 |
10 |
12 |
| Authors’ Response to: “Health Opportunity Costs and Expert Elicitation: A Comment on Soares et al.†by Sampson, Firth, and Towse |
0 |
0 |
0 |
1 |
4 |
4 |
6 |
9 |
| CAUSES FOR CONCERN: IS NICE FAILING TO UPHOLD ITS RESPONSIBILITIES TO ALL NHS PATIENTS? |
0 |
0 |
0 |
7 |
2 |
3 |
12 |
52 |
| Catalogue of EQ-5D Scores for the United Kingdom |
2 |
7 |
18 |
58 |
6 |
18 |
52 |
135 |
| Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs |
0 |
0 |
0 |
0 |
1 |
3 |
9 |
15 |
| Cost-Effectiveness Analysis Using Data from Multinational Trials: The Use of Bivariate Hierarchical Modeling |
0 |
0 |
0 |
0 |
2 |
2 |
7 |
8 |
| Cost-Effectiveness Analysis of Acupuncture, Counselling and Usual Care in Treating Patients with Depression: The Results of the ACUDep Trial |
0 |
0 |
1 |
1 |
3 |
5 |
14 |
25 |
| Cost-Effectiveness Analysis of Treatments for Chronic Disease: Using R to Incorporate Time Dependency of Treatment Response |
0 |
0 |
0 |
4 |
1 |
3 |
11 |
26 |
| Cost-effectiveness of adjunct non-pharmacological interventions for osteoarthritis of the knee |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
5 |
| Costs Incurred by Patients Undergoing Advanced Colorectal Cancer Therapy |
0 |
0 |
0 |
11 |
1 |
2 |
6 |
205 |
| Dangerous omissions: the consequences of ignoring decision uncertainty |
0 |
1 |
1 |
8 |
0 |
3 |
5 |
38 |
| Developing the EQ-5D-5L Value Set for Uganda Using the ‘Lite’ Protocol |
0 |
0 |
1 |
1 |
0 |
0 |
11 |
16 |
| Discounting and cost‐effectiveness in NICE – stepping back to sort out a confusion |
0 |
0 |
0 |
88 |
1 |
2 |
7 |
309 |
| Distributional cost effectiveness analysis of West Yorkshire low emission zone policies |
0 |
0 |
0 |
2 |
1 |
1 |
9 |
22 |
| Effect of Treatment Interruption and Intensification of Antiretroviral Therapy on Health-Related Quality of Life in Patients with Advanced HIV |
0 |
0 |
0 |
0 |
2 |
4 |
8 |
12 |
| Efficiency, Equity, and Budgetary Policies |
0 |
0 |
0 |
0 |
0 |
3 |
10 |
16 |
| Establishing the Value of Diagnostic and Prognostic Tests in Health Technology Assessment |
0 |
0 |
0 |
1 |
1 |
2 |
6 |
13 |
| Estimating mean QALYs in trial‐based cost‐effectiveness analysis: the importance of controlling for baseline utility |
0 |
0 |
6 |
99 |
3 |
7 |
27 |
350 |
| Estimating the global demand curve for a leishmaniasis vaccine: A generalisable approach based on global burden of disease estimates |
0 |
0 |
0 |
0 |
2 |
4 |
10 |
10 |
| Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients served by health systems |
0 |
0 |
0 |
1 |
1 |
3 |
8 |
16 |
| Estimating utility data from clinical indicators for patients with stable angina |
0 |
0 |
0 |
4 |
0 |
2 |
6 |
31 |
| Evidence synthesis, parameter correlation and probabilistic sensitivity analysis |
0 |
0 |
0 |
69 |
1 |
2 |
13 |
280 |
| Future Directions for Cost-effectiveness Analyses in Health and Medicine |
0 |
0 |
0 |
1 |
2 |
2 |
4 |
19 |
| Golimumab for the Treatment of Psoriatic Arthritis |
0 |
0 |
0 |
7 |
2 |
4 |
7 |
168 |
| Health Opportunity Costs: Assessing the Implications of Uncertainty Using Elicitation Methods with Experts |
0 |
0 |
0 |
2 |
2 |
7 |
15 |
26 |
| Health-related quality of life implications of plantar ulcers resulting from neuropathic damage caused by leprosy: An analysis from the trial of autologous blood products (TABLE trial) in Nepal |
0 |
0 |
0 |
0 |
2 |
3 |
11 |
11 |
| How to Invest in Getting Cost-effective Technologies into Practice? A Framework for Value of Implementation Analysis Applied to Novel Oral Anticoagulants |
0 |
0 |
0 |
0 |
0 |
3 |
14 |
15 |
| How to design the cost‐effectiveness appraisal process of new healthcare technologies to maximise population health: A conceptual framework |
0 |
0 |
0 |
5 |
2 |
6 |
10 |
32 |
| Identifying Research Priorities: The Value of Information Associated with Repeat Screening for Age-Related Macular Degeneration |
0 |
0 |
0 |
1 |
2 |
3 |
7 |
9 |
| Income Effects of Reduced Health and Health Effects of Reduced Income |
0 |
0 |
0 |
0 |
3 |
5 |
9 |
9 |
| Jointly Modelling Economics and Epidemiology to Support Public Policy Decisions for the COVID-19 Response: A Review of UK Studies |
0 |
0 |
0 |
1 |
0 |
0 |
12 |
32 |
| Methods Development for Health Technology Assessment |
0 |
1 |
1 |
1 |
3 |
8 |
9 |
9 |
| Methods for assessing the cost-effectiveness of public health interventions: Key challenges and recommendations |
0 |
0 |
0 |
84 |
1 |
5 |
19 |
300 |
| Model Parameter Estimation and Uncertainty Analysis |
0 |
0 |
1 |
1 |
3 |
6 |
15 |
24 |
| Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra |
0 |
0 |
0 |
159 |
4 |
8 |
15 |
623 |
| Program Evaluation of Population- and System-Level Policies: Evidence for Decision Making |
0 |
0 |
0 |
0 |
1 |
2 |
6 |
12 |
| Real Economics Needs to Reflect Real Decisions |
0 |
0 |
0 |
23 |
1 |
1 |
5 |
91 |
| Recognising diversity in public preferences: the use of preference sub‐groups in cost‐effectiveness analysis. Authors' reply |
0 |
0 |
0 |
4 |
0 |
1 |
6 |
52 |
| Recognizing diversity in public preferences: The use of preference sub‐groups in cost‐effectiveness analysis |
0 |
0 |
0 |
13 |
2 |
2 |
9 |
119 |
| Recombinant Erythropoietin for Chemotherapy-Related Anaemia |
0 |
0 |
1 |
24 |
1 |
3 |
8 |
228 |
| Reflecting the real value of health care resources in modelling and cost-effectiveness studies—The example of viral load informed differentiated care |
0 |
0 |
0 |
0 |
3 |
8 |
14 |
24 |
| Representing uncertainty: the role of cost‐effectiveness acceptability curves |
0 |
2 |
4 |
179 |
8 |
13 |
33 |
542 |
| Sensitivity analysis in economic evaluation: A review of published studies |
0 |
0 |
4 |
18 |
2 |
3 |
18 |
106 |
| Shared treatment decision making in a collectively funded health care system: possible conflicts and some potential solutions |
0 |
0 |
0 |
4 |
0 |
0 |
1 |
24 |
| Should the Lambda (λ) Remain Silent? |
0 |
0 |
0 |
5 |
4 |
5 |
7 |
36 |
| Sins of omission and obfuscation: IQWIG's guidelines on economic evaluation methods |
0 |
0 |
0 |
27 |
3 |
4 |
7 |
115 |
| Social value and individual choice: The value of a choice‐based decision‐making process in a collectively funded health system |
0 |
0 |
0 |
0 |
1 |
2 |
9 |
17 |
| Striving for a Societal Perspective: A Framework for Economic Evaluations When Costs and Effects Fall on Multiple Sectors and Decision Makers |
0 |
0 |
1 |
8 |
3 |
4 |
15 |
71 |
| The Value of Heterogeneity for Cost-Effectiveness Subgroup Analysis |
0 |
0 |
0 |
1 |
0 |
1 |
8 |
16 |
| The Value of Implementation and the Value of Information: Combined and Uneven Development |
0 |
0 |
0 |
0 |
4 |
4 |
11 |
13 |
| The cost‐effectiveness of preference‐based treatment allocation: the case of hysterectomy versus endometrial resection in the treatment of menorrhagia |
0 |
0 |
0 |
0 |
1 |
1 |
9 |
56 |
| Unfinished Symphony: A Tribute to the Life and Career of Bernie O’Brien (1959–2004) |
0 |
0 |
0 |
0 |
2 |
4 |
7 |
7 |
| Using Age-Specific Values for Pediatric HRQoL in Cost-Effectiveness Analysis: Is There a Problem to Be Solved? If So, How? |
0 |
0 |
0 |
0 |
0 |
2 |
3 |
3 |
| We need to talk about values: a proposed framework for the articulation of normative reasoning in health technology assessment |
0 |
0 |
0 |
1 |
0 |
1 |
8 |
10 |
| What is the Quality of Economic Evaluations of Non-Drug Therapies? A Systematic Review and Critical Appraisal of Economic Evaluations of Radiotherapy for Cancer |
0 |
0 |
0 |
3 |
2 |
4 |
9 |
41 |
| Whither trial‐based economic evaluation for health care decision making? |
1 |
1 |
1 |
65 |
1 |
7 |
13 |
280 |
| Total Journal Articles |
3 |
12 |
41 |
1,117 |
119 |
244 |
691 |
5,541 |
LogEc is hosted by the
Örebro University School of Business.